(19)
(11) EP 4 771 131 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 23782333.1

(22) Date of filing: 01.09.2023
(51) International Patent Classification (IPC): 
C12N 5/09(2010.01)
(52) Cooperative Patent Classification (CPC):
C12N 5/0693; C12N 2501/15; C12N 2501/727; C12N 2513/00; C12N 2510/00; C12N 2503/02; C12N 2501/115; C12N 2500/38
(86) International application number:
PCT/US2023/031857
(87) International publication number:
WO 2025/048833 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(71) Applicant: Taipei Medical University
Taipei City 110 (TW)

(72) Inventors:
  • SHEN, Yao-An
    Taipei City, 110 (TW)
  • WU, Chieh-Hsi
    Covina, CA 91792 (US)

(74) Representative: Cabinet Chaillot 
16/20, avenue de l'Agent Sarre B.P. 74
92703 Colombes Cedex
92703 Colombes Cedex (FR)

   


(54) CANCER STEM CELL SERUM-FREE CONDITIONED MEDIUM, AND USE THEREOF IN A QUADRUPLE SELECTING METHOD FOR CANCER STEM CELL LINE, AND THE ISOLATED CANCER STEM CELL LINE